Year archive

Prestige BioPharma Limited — 2025 filings

All 26 regulatory filings released by Prestige BioPharma Limited (950210) in 2025, sourced directly from the official regulator.

26 Filings

2025 Period

2025 filings (26)

Filing	Released	Lang
단일판매ㆍ공급계약체결 Capital/Financing Update	2025-11-03	Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고 Board/Management Information	2025-10-31	Korean
단일판매ㆍ공급계약체결 Regulatory Filings	2025-10-29	Korean
주식등의대량보유상황보고서(일반) Major Shareholding Notification	2025-10-13	Korean
유가증권시장상장외국법인외부감사인선임ㆍ해임ㆍ변경신고서 Audit Report / Information	2025-09-30	Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고 Board/Management Information	2025-09-29	Korean
정기주주총회결과 Declaration of Voting Results & Voting Rights Announcements	2025-09-29	Korean
[기재정정]사업보고서 (2025.06) Annual Report FY 2025	2025-09-23	Korean
[기재정정]사업보고서 (2025.06) Annual Report FY 2025	2025-09-23	Korean
감사보고서제출 Audit Report / Information FY 2025	2025-09-19	Korean
사업보고서 (2025.06) Annual Report FY 2025	2025-09-19	Korean
[기재정정]단일판매ㆍ공급계약체결 Regulatory Filings	2025-09-16	Korean
[기재정정]주주총회소집결의 AGM Information	2025-09-11	Korean
주주총회소집공고 AGM Information	2025-09-11	Korean
주주총회소집결의 AGM Information	2025-09-09	Korean
단일판매ㆍ공급계약체결 Regulatory Filings	2025-08-18	Korean
매출액또는손익구조30%(대규모법인은15%)이상변경 Earnings Release FY 2025	2025-08-13	Korean
[기재정정]투자판단관련주요경영사항 (특허권 취득) Regulatory Filings	2025-07-31	Korean
기타경영사항(자율공시) (제10기 정기주주총회 권리주주 확정을 위한 증권예탁증권 기준일 설정 공고) AGM Information	2025-06-13	Korean
기업지배구조보고서공시 Governance Information	2025-05-30	Korean
분기보고서 (2025.03) Interim / Quarterly Report Q3 2025	2025-05-30	Korean
투자판단관련주요경영사항 (Tuznue (HD201,Trastuzumab 바이오시밀러) 판매에 대한 라이선스 및 공급 계약 체결) M&A Activity	2025-05-26	Korean
반기보고서 (2024.12) Interim / Quarterly Report H1 2024	2025-02-28	Korean
주식등의대량보유상황보고서(약식) Major Shareholding Notification	2025-02-13	Korean
임원ㆍ주요주주특정증권등소유상황보고서 Director's Dealing	2025-02-13	Korean
임원ㆍ주요주주특정증권등거래계획보고서 Major Shareholding Notification	2025-01-09	Korean